ABT-806

DRUG4 trials

Sponsors

AbbVie (prior sponsor, Abbott), University of Chicago

Conditions

AdenocarcinomaAdvanced Solid Tumors

Phase 1

A Study of ABT-806 in Subjects With Advanced Solid Tumor Types

CompletedNCT01255657

AbbVie (prior sponsor, Abbott)Advanced Solid Tumors

Start: 2010-11-30End: 2012-11-30Updated: 2017-11-21

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

CompletedNCT01406119

AbbVie (prior sponsor, Abbott)Advanced Solid Tumors

Start: 2011-10-31End: 2017-01-31Updated: 2017-01-27

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types

CompletedNCT01472003

AbbVie (prior sponsor, Abbott)Advanced Solid Tumors

Start: 2011-10-31End: 2012-12-31Updated: 2013-01-14

Phase 2

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

CompletedNCT02213289

University of ChicagoAdenocarcinoma

Start: 2015-01-20End: 2020-08-20Updated: 2021-04-08

Related Papers

Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses.

Journal of Clinical Oncology2020-05-204 citations

Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289).

Journal of Clinical Oncology2020-02-016 citations

Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289).

Journal of Clinical Oncology2018-02-0110 citations

Anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma.

Journal of Clinical Oncology2017-02-01